Registration Opens for SOVEREIGN 2026, New Partnership Opportunities with Canurta Naturals, and Continued Progress Toward PharmaDrug 2nd Tranche
- Canurta
- Apr 8
- 2 min read
Canurta Co-Hosts SOVEREIGN 2026 During Toronto Tech Week
Canurta Therapeutics, in collaboration with International Business University (IBU), is co-hosting SOVEREIGN 2026, a one-day flagship event taking place on May 28, 2026, in downtown Toronto as part of Toronto Tech Week.
The event will convene founders, technologists, institutional leaders, and students to explore the intersection of human performance, decentralized finance, and artificial intelligence. Through curated discussions, SOVEREIGN 2026 is designed to bridge academic research, venture development, and next-generation talent.
Centered on the theme of sovereignty, the event reflects growing focus on resilience, ownership, and technological leadership in an increasingly complex global environment.
Partnership Opportunities with Canurta Naturals
Canurta Naturals, Canurta Therapeutics’ sister company focused on ingredient manufacturing and supply, is actively seeking new partners across standardized botanical ingredients, bulk supply, and formulation collaboration.
As Canurta continues to build across therapeutic and commercial pathways, Canurta Naturals supports broader industry engagement through manufacturing capabilities designed to meet a range of partner needs.
To explore partnership opportunities, connect with the team below.
R&D Update: Upcoming Pre-CTA Meeting with Health Canada
Canurta’s R&D team is preparing for a pre-Clinical Trial Application (pre-CTA) meeting with Health Canada regarding a new botanical extract under development.
This upcoming meeting represents an important early regulatory step and will help inform development planning as the program advances through evaluation.
Canurta Continues Progress Toward Second Tranche Closing with PharmaDrug Inc.
Canurta continues to advance the work required for closing the second tranche of its transaction with PharmaDrug Inc. The first tranche closed in January, with PharmaDrug acquiring an initial 19.9% equity interest in Canurta under the previously announced two-tranche structure.
As this process moves forward, Canurta remains focused on completing the required audit and related transaction steps with care and discipline. We look forward to providing further updates as milestones are reached.
